What systemic treatment would you offer for metastatic HER2+ breast cancer that has progressed through THP and TDM-1 with predominant CNS progression and without localized treatment options?
Given the changing landscape of treatment, some patients may have already received capecitabine previously. Would this impact your treatment recommendations?
Community PollStarted
What systemic treatment would you offer for metastatic HER2+ breast cancer that has progressed through THP and TDM-1 with predominant CNS progression and without localized treatment options?
76 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
For patients after 2 standard lines of HER2-targeted therapies with CNS progression who are not candidates for local CNS therapy, my first option would be to use trastuzumab plus tucatinib (with capecitabine if not previously used) if available (e.g. single patient IND). There is demonstrated activi...
Join for free or sign in to see the full answer